Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Biosergen advances antifungal drug with strong Q1 results

Biosergen

Biosergen’s Q1 report highlights the successful completion of the second patient cohort in its BSG005 proof-of-concept clinical trial, targeting life-threatening fungal infections. CEO Tine Olesen describes the results as demonstrating real therapeutic potential, paving the way for the third cohort in Q4 2025. We reached out to Olesen for a comment.

Read the interview at biostock.se:

https://biostock.se/en/2025/05/biosergen-advances-antifungal-drug-with-strong-q1-results/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.